StoxDr. Lal Path Labs vs Piramal Pharma: share price & financials comparison
NSE: LALPATHLAB vs PPLPHARMA · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Dr. Lal Path Labs vs Piramal Pharma at a glance
Dr. Lal Path Labs (LALPATHLAB) has a market capitalisation of ₹33,057 Cr, against ₹31,791 Cr for Piramal Pharma (PPLPHARMA). Over the past year Dr. Lal Path Labs has returned +27.5%, compared with +17.2% for Piramal Pharma. Dr. Lal Path Labs earns a higher return on equity (21.3% vs -2.6%). Dr. Lal Path Labs comes out ahead on size and profitability. Piramal Pharma comes out ahead on momentum and technicals. Across the scored metrics below, Dr. Lal Path Labs leads on 7 and Piramal Pharma on 6. On StoxGud's 10-point checklist, Dr. Lal Path Labs scores 9/10 and Piramal Pharma scores 6/10.
| Metric | Dr. Lal Path Labs | Piramal Pharma |
|---|---|---|
| Size | ||
| Market cap | ₹33,057 Cr | ₹31,791 Cr |
| Revenue (latest FY) | ₹2,763 Cr | ₹8,869 Cr |
| Net profit (latest FY) | ₹505 Cr | ₹-326 Cr |
| Valuation | ||
| P/E | 56.7 | — |
| P/B | 12.04 | 3.90 |
| Dividend yield | 0.67% | 0.06% |
| Profitability | ||
| Return on equity | 21.3% | -2.6% |
| Net profit margin | 19.2% | -2.1% |
| Operating margin | 29.5% | 12.3% |
| Growth | ||
| Revenue growth (YoY) | +19.6% | +28.1% |
| Net profit growth (YoY) | +27.6% | — |
| Revenue CAGR (multi-year) | +11.8% | +7.8% |
| Financial health | ||
| Debt to equity | 0.00 | 0.70 |
| Momentum | ||
| 1-month return | +1.3% | +17.9% |
| 1-year return | +27.5% | +17.2% |
| 3-year CAGR | +14.2% | +30.2% |
| 5-year CAGR | +1.5% | — |
| 10-year CAGR | +12.9% | — |
| Distance from 52W high | -2.9% | -0.3% |
| Technicals | ||
| RSI (14) | 65 | 76 |
| Price vs 200-day avg | +19.3% | +33.9% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Dr. Lal Path Labs | Piramal Pharma |
|---|---|---|
| Price above 50-day average | ✓ | ✓ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✓ | ✗ |
| Positive 1-year return | ✓ | ✓ |
| Return on equity above 15% | ✓ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✓ | ✗ |
| P/E below industry median | ✗ | ✗ |
| Score | 9/10 | 6/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Dr. Lal Path Labs or Piramal Pharma?
Dr. Lal Path Labs has a market cap of ₹33,057 Cr and Piramal Pharma has a market cap of ₹31,791 Cr as of 06 Nov 2026.
Which gave better returns in the last year, Dr. Lal Path Labs or Piramal Pharma?
Dr. Lal Path Labs did better: Dr. Lal Path Labs returned +27.5% and Piramal Pharma returned +17.2% over one year.
Is Dr. Lal Path Labs or Piramal Pharma a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Dr. Lal Path Labs scores 9/10 and Piramal Pharma scores 6/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.